Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

– Current median durability of response (mDOR) of CRc's = 6 months and increasing (n=9) – Recruitment increased to 22 subjects and CRc's in all subjects evaluable for efficacy (n=20) was 45% – Data presented at European Hematology Association (EHA) 2024 Hybrid Congress and Company KOL Meeting in Madrid Preliminary Results Across All Lines of TreatmentPreliminary Results Across All Lines of Treatment Median Durability of ResponseMedian Durability of Response Response by Genotype and Mutations Response by Gen ...